vimarsana.com
Home
Live Updates
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society : vimarsana.com
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks
More than 75% of participants achieved
Related Keywords
Italy ,
Roland Chen ,
Bristol Myers Squibb ,
Instagram ,
Cenexel Hassman Research Institute ,
Exchange Commission ,
Twitter ,
Facebook ,
Youtube ,
Schizophrenia International Research Society ,
Linkedin ,
Annual Congress ,
Bristol Myers ,
Negative Syndrome Scale ,
Clinical Global Impression Severity ,
Elan Cohen ,
Oral Session ,
New Pharmacological Treatments ,
Myers Squibb ,
Delivering Breakthrough Science ,
Meaningful Interventions ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
vimarsana.com © 2020. All Rights Reserved.